1. Metronomics: towards personalized chemotherapy?
   Nicolas André et al, 2014, Nature Reviews Clinical Oncology CrossRef
2. Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience
   Cem Simsek et al, 2019, Journal of Oncology CrossRef
3. Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer
   Mustafa Asowed et al, 2023, BMC Cancer CrossRef
4. Cytotoxics and Anti-Angiogenics: Metronomic Therapies
   Andreas Pircher et al, 2017, Tumor Angiogenesis CrossRef
5. Population-based study on use of chemotherapy in men with castration resistant prostate cancer
   Ingela Franck Lissbrant et al, 2013, Acta Oncologica CrossRef
6. Cytotoxics and Anti-angiogenics: Metronomic Therapies
   Andreas Pircher et al, 2019, Tumor Angiogenesis CrossRef
7. Clinical Trials of Low-Dose Metronomic Chemotherapy in Castration-Resistant Prostate Cancer
   Keemo Delos Santos et al, 2014, Metronomic Chemotherapy CrossRef
8. Metronomic chemotherapy from rationale to clinical studies: A dream or reality?
   Antonio Gnoni et al, 2015, Critical Reviews in Oncology/Hematology CrossRef
9. Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial
   Fabien Calcagno et al, 2016, Medical Oncology CrossRef
10. De-escalating cancer treatments during COVID 19 pandemic: Is metronomic chemotherapy a reasonable option?
    Palma Fedele et al, 2021, Critical Reviews in Oncology/Hematology CrossRef
11. Metronomic Chemotherapy for Advanced Prostate Cancer: A Literature Review
    Shruti Parshad et al, 2022, Journal of Clinical Medicine CrossRef
12. Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature
    Isabel Tena et al, 2018, Clinical Medicine Insights: Oncology CrossRef
13. Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer
    Taraswi Mitra Ghosh et al, 2021, Frontiers in Pharmacology CrossRef
14. A registry-based study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide
    Mohammed Alghazali et al, 2019, Scandinavian Journal of Urology CrossRef